Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Group leaders in the Departments of Biochemistry (Profs Christina Redfield, Jason Schnell and John Vakonakis) and Chemistry (Profs. Andy Baldwin and Tim Claridge) have secured support towards upgrading the flagship 950 MHz nuclear magnetic resonance (NMR) spectrometer, housed in Biochemistry.

Funding of close to £500K has been obtained from the Engineering and Physical Sciences Research Council (EPSRC) under the “Very- and Ultra-High field NMR for the physical and life sciences” initiative. The 950 MHz NMR upgrade will include a high-sensitivity 5mm TCI “CryoProbe” and an automated sample changer. This new probe will increase 1H signal-to-noise by a factor of up to 3, allowing more challenging macromolecular systems to be studied. The sample changer will improve throughput by enabling fully automated, round-the-clock data collection. Once upgraded, time on the 950 MHz NMR spectrometer will also be made available to external users from other UK academic institutions and from industry. 

Find out more (Department of Biochemistry website)

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.